BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.17.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260730T193000
DTEND;TZID=Africa/Nairobi:20260730T203000
DTSTAMP:20260820T222730Z
CREATED:20260728T131820Z
LAST-MODIFIED:20260820T222730Z
UID:41839-1785439800-1785443400@kesho-kenya.org
SUMMARY:Implementing Precision Oncology in LMICs
DESCRIPTION:Implementing Precision Oncology in LMICs:\nFrom Diagnosis to Clinical Decision-Making \nDate: 30th July 2026\nTime: 7 PM – 8:30 PM EAT \nSpeaker\nProf. Shahin Sayed\nAssociate Professor & Consultant\, Anatomical Pathology and Cytology\, Department of Pathology\, Medical College\, Aga Khan University; Chair & Laboratory Director. Pathology\, AKUH\, N\nThe Diagnostic Foundations of Precision Oncology: Pathology\, Biomarkers and Molecular Testing \nSpeaker\nProf. Chite Asirwa\nMedical Oncologist & Hematologist; CEO\, International Cancer Institute\nPrecision Oncology in LMICs: Current Landscape\, Clinical Application and the Road Ahead \nModerator\nProf. Nicholas Abinya\nConsultant Medical Oncologist\, Nairobi Hospital Cancer Centre \nSummary\nThis session examined what meaningful precision oncology looks like in low- and middle-income countries\, connecting clinical decision-making with pathology\, molecular diagnostics\, patient factors\, health-system capacity and access to treatment. \nA central theme was that precision oncology is broader than genomic sequencing. Prof. Chite Asirwa described it as the integration of clinical\, pathological\, molecular\, environmental and patient-specific information across diagnosis\, prognosis\, treatment selection and monitoring. Used well\, this approach can reduce ineffective empirical treatment\, limit unnecessary toxicity and direct limited resources towards interventions most likely to benefit the patient. \nProf. Shahin Sayed focused on the diagnostic foundations that make precision care possible. High-quality tissue\, correct fixation and handling\, validated assays\, quality assurance and clinically useful reporting all determine whether a molecular result can be trusted. The discussion reinforced that advanced testing cannot compensate for weak foundational pathology\, and that essential immunohistochemistry and biomarker testing remain an important starting point for many settings. \nThe session also addressed Africa’s underrepresentation in genomic datasets and the challenge of interpreting variants when locally relevant reference data are limited. Molecular results need clinical context and\, where possible\, multidisciplinary interpretation. Liquid biopsy and circulating tumour DNA were discussed as promising tools for selected applications\, but standardisation\, quality control and careful use remain important\, particularly when considering screening. \nImplementation was therefore framed as a phased health-system journey rather than a technology purchase. Strong pathology services\, reliable essential biomarkers\, regional molecular capacity\, better patient navigation\, financing and locally generated data must develop together. Across the session\, a consistent message emerged: precision oncology has greatest value when a reliable test leads to a clinically meaningful decision and an accessible treatment pathway. \nKey Takeaways\n\nPrecision oncology integrates clinical\, pathological\, molecular and patient-specific information rather than genomics alone.\nAccurate pathology\, specimen quality and laboratory quality assurance are foundational to every precision treatment decision.\nEssential biomarkers and immunohistochemistry should be strengthened before indiscriminate expansion into complex testing.\nAfrican genomic data and multidisciplinary interpretation are needed to improve the relevance of molecular results.\nTesting has limited value when results cannot be linked to accessible treatment\, making financing and patient navigation part of precision care.\n\nContinue the learning \nThis summary captures only part of the discussion. To request the full session recording\, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.
URL:https://kesho-kenya.org/event/implementing-precision-oncology-in-lmics/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/07/WhatsApp-Image-2026-07-28-at-12.07.44-PM-3-e1785245724838.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260806T193000
DTEND;TZID=Africa/Nairobi:20260806T203000
DTSTAMP:20260820T224450Z
CREATED:20260820T224041Z
LAST-MODIFIED:20260820T224450Z
UID:41901-1786044600-1786048200@kesho-kenya.org
SUMMARY:Ovarian Cancer in Focus
DESCRIPTION:Ovarian Cancer in Focus: Innovation\, Care and Evolving Care\n\nModerator: Dr. Amina K. Habib\nSpeaker: Dr. Chris Gallagher\nDate: 6 August 2026\n\nSummary\nThis session examined recent developments in epithelial ovarian cancer\, from the continuing challenge of earlier diagnosis to surgical decision-making\, molecular stratification\, maintenance therapy and emerging options for recurrent and platinum-resistant disease. \nA central theme was the move towards increasingly biomarker-informed care. Dr. Chris Gallagher highlighted how BRCA1/2 mutations and homologous recombination deficiency are shaping treatment selection\, particularly PARP inhibitor maintenance after response to platinum-based chemotherapy. The discussion reinforced that these therapies offer the greatest value when matched to tumour biology rather than applied broadly. \nThe session also explored the challenge of finding ovarian cancer earlier. Emerging approaches using circulating DNA fragments may improve future detection\, but the evidence remains preliminary and requires wider validation. Surgical treatment was similarly framed around careful patient selection: the choice between upfront cytoreductive surgery and neoadjuvant chemotherapy should reflect disease extent\, patient fitness and the likelihood of achieving complete resection. \nFor recurrent and difficult-to-treat disease\, the discussion highlighted newer approaches including folate receptor alpha-targeted antibody-drug conjugates in platinum-resistant ovarian cancer and molecularly targeted strategies for low-grade serous disease. These developments are expanding treatment possibilities\, although the role of immunotherapy remains less clearly established. \nThe discussion brought these advances into the African context\, where access to BRCA and HRD testing\, targeted therapies and newer medicines remains uneven. Molecular testing is most meaningful when it can inform an accessible treatment pathway. In recurrent disease especially\, expected benefit must be weighed against toxicity\, quality of life\, patient fitness and financial burden. \nAcross the session\, a consistent message emerged: ovarian cancer care is becoming increasingly defined by tumour biology\, but improved outcomes still depend on appropriate surgery\, access to molecular testing\, careful patient selection and treatment pathways that reflect both evidence and real-world access. \nKey Takeaways\n\nEarlier detection remains a major unmet need\, with emerging circulating DNA approaches still requiring further validation.\nBRCA and homologous recombination status are increasingly important in guiding treatment selection.\nSurgical sequencing should be individualised\, with complete cytoreduction remaining an important treatment objective.\nPARP inhibitors and newer targeted therapies are expanding options for selected patients\, including those with recurrent or platinum-resistant disease.\nIn African settings\, clinical benefit\, treatment access\, affordability and quality of life must remain central to decision-making.\n\nContinue the learning \nThis summary captures only part of the discussion. To request the full session recording\, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.
URL:https://kesho-kenya.org/event/ovarian-cancer-in-focus/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/08/Ovarian-Cancer-in-Focus-e1787265870600.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260813T193000
DTEND;TZID=Africa/Nairobi:20260813T203000
DTSTAMP:20260811T142645Z
CREATED:20260811T142028Z
LAST-MODIFIED:20260811T142645Z
UID:41876-1786649400-1786653000@kesho-kenya.org
SUMMARY:From Digital Diagnosis to Connected Cancer Care
DESCRIPTION:“From Digital Diagnosis to Connected Cancer Care” \nCPD ACCREDITED \nDate: 13th August 2026\nTime: 7 PM – 8:30 PM EAT \nSpeaker: Dr. Arvind Rao\nProfessor\, Department of Computational Medicine and Bioinformatics\, University of Michigan\nTalk: “From Digital Diagnosis to AI-Powered Cancer Care: Governance\, LLMs\, and the Connected Future” \nSpeaker: Dr. Joshua Kibera\nAnatomical Pathologist\, CEO/Founder – The Pathology Network\nTalk: “Beyond the Algorithm: Building the Digital Diagnostic Infrastructure for AI-Enabled Precision Cancer Care” \nModerator: Dr. Anne Korir\nSenior Research Scientist\, Kenya Medical Research Institute (KEMRI) \n    	\n        Click to Register
URL:https://kesho-kenya.org/event/from-digital-diagnosis-to-connected-cancer-care/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/08/WhatsApp-Image-2026-08-11-at-10.35.44-AM-e1786457992618.jpeg
END:VEVENT
END:VCALENDAR